Insulin Resistance Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
Powered by
All the vital news, analysis, and commentary curated by our industry experts.
Insulin Resistance Pipeline Drugs Market Overview
Insulin resistance pipeline drugs market research report provides comprehensive information on the therapeutics under development for Insulin Resistance, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Insulin Resistance and features dormant and discontinued projects.
Key Targets in the Insulin Resistance Pipeline Market
The key targets in the insulin resistance pipeline market are Galectin 3, Glucagon Receptor, Insulin Like Growth Factor Binding Protein 2, Leptin Receptor, N-Glycosylase/DNA Lyase, O2 Radical, Oxytocin Receptor, and Protein Phosphatase 2A.
Key MoA in the Insulin Resistance Pipeline Market
The key MoA in the insulin resistance pipeline market are Galectin 3 Inhibitor, Glucagon Receptor Agonist, Insulin Like Growth Factor Binding Protein 2 Inhibitor, Leptin Receptor Agonist, N-Glycosylase/DNA Lyase Activator, O2 Radical Scavenger, Oxytocin Receptor Agonist, and Protein Phosphatase 2A Inhibitor.
Key RoA in the Insulin Resistance Pipeline Drugs Market
The key RoA in the insulin resistance pipeline drugs market are oral, intravenous, subcutaneous, and nasal. Oral has the highest number of pipeline products.
Insulin Resistance Pipeline Drugs Market, by RoA
For more RoA insights, download a free report sample
Key Molecule Types in the Insulin Resistance Pipeline Market
The key molecule types in the insulin resistance pipeline market are small molecule, recombinant peptide, recombinant protein, synthetic peptide, fusion protein, and peptide. Small molecule has the highest number of pipeline products.
Insulin Resistance Pipeline Market, by Molecule Type
For more molecule type insights, download a free report sample
Key Companies in the Insulin Resistance Pipeline Drugs Market
The key companies in the insulin resistance pipeline drugs market are NorthSea Therapeutics BV, Amolyt Pharma, Amryt Pharma Plc, CohBar Inc, Exscien Corp, Glycomantra Inc, Hanmi Pharmaceuticals Co Ltd, Lixte Biotechnology Holdings Inc, The Healthy Aging Co, and Trigemina Inc. NorthSea Therapeutics BV has the highest number of pipeline products.
Insulin Resistance Pipeline Drugs Market, by Companies
To know more about key companies, download a free report sample
Market report overview
Key taregts | Galectin 3, Glucagon Receptor, Insulin Like Growth Factor Binding Protein 2, Leptin Receptor, N-Glycosylase/DNA Lyase, O2 Radical, Oxytocin Receptor, and Protein Phosphatase 2A |
Key MoA | Galectin 3 Inhibitor, Glucagon Receptor Agonist, Insulin Like Growth Factor Binding Protein 2 Inhibitor, Leptin Receptor Agonist, N-Glycosylase/DNA Lyase Activator, O2 Radical Scavenger, Oxytocin Receptor Agonist, and Protein Phosphatase 2A Inhibitor |
Key RoA | Oral, Intravenous, Subcutaneous, and Nasal |
Key molecule types | Small Molecule, Recombinant Peptide, Recombinant Protein, Synthetic Peptide, Fusion Protein, and Peptide |
Key companies | NorthSea Therapeutics BV, Amolyt Pharma, Amryt Pharma Plc, CohBar Inc, Exscien Corp, Glycomantra Inc, Hanmi Pharmaceuticals Co Ltd, Lixte Biotechnology Holdings Inc, The Healthy Aging Co, and Trigemina Inc |
Scope
- The pipeline guide provides a snapshot of the global therapeutic landscape of Insulin Resistance (Metabolic Disorders).
- The pipeline guide reviews pipeline therapeutics for Insulin Resistance (Metabolic Disorders) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Insulin Resistance (Metabolic Disorders) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Insulin Resistance (Metabolic Disorders) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Insulin Resistance (Metabolic Disorders)
Reasons to Buy
- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Insulin Resistance (Metabolic Disorders).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Insulin Resistance (Metabolic Disorders) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Amryt Pharma Plc
CohBar Inc
Exscien Corp
Glycomantra Inc
Hanmi Pharmaceuticals Co Ltd
Lixte Biotechnology Holdings Inc
NorthSea Therapeutics BV
The Healthy Aging Co
Trigemina Inc
Table of Contents
Table
Figures
Frequently asked questions
-
What are the key targets in the insulin resistance pipeline market?
The key targets in the insulin resistance pipeline market are Galectin 3, Glucagon Receptor, Insulin Like Growth Factor Binding Protein 2, Leptin Receptor, N-Glycosylase/DNA Lyase, O2 Radical, Oxytocin Receptor, and Protein Phosphatase 2A.
-
What are key MoA in the insulin resistance pipeline market?
The key MoA in the insulin resistance pipeline market are Galectin 3 Inhibitor, Glucagon Receptor Agonist, Insulin Like Growth Factor Binding Protein 2 Inhibitor, Leptin Receptor Agonist, N-Glycosylase/DNA Lyase Activator, O2 Radical Scavenger, Oxytocin Receptor Agonist, and Protein Phosphatase 2A Inhibitor.
-
What are the key RoA in the insulin resistance pipeline market?
The key RoA in the insulin resistance pipeline market are oral, intravenous, subcutaneous, and nasal.
-
What are the key molecule types in the insulin resistance pipeline market?
The key molecule types in the insulin resistance pipeline market are small molecule, recombinant peptide, recombinant protein, synthetic peptide, fusion protein, and peptide.
-
What are the key companies in the insulin resistance pipeline market?
The key companies in the insulin resistance pipeline market are NorthSea Therapeutics BV, Amolyt Pharma, Amryt Pharma Plc, CohBar Inc, Exscien Corp, Glycomantra Inc, Hanmi Pharmaceuticals Co Ltd, Lixte Biotechnology Holdings Inc, The Healthy Aging Co, and Trigemina Inc.
Get in touch to find out about multi-purchase discounts
reportstore@globaldata.com
Tel +44 20 7947 2745
Every customer’s requirement is unique. With over 220,000 construction projects tracked, we can create a tailored dataset for you based on the types of projects you are looking for. Please get in touch with your specific requirements and we can send you a quote.